Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Francine L. Healy"'
Autor:
Lizbeth Gallagher, Yulia Benitex, Matthew D. Hill, Richard E. Olson, Nicholas J. Lodge, Francine L. Healy, Debra J. Post-Munson, John E. Macor, Sivarao V. Digavalli, Daniel G. Morgan, JoAnne E Natale, Linda J. Bristow, Ping Chen, Haiquan Fang
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:578-581
We describe the synthesis of quinuclidine-containing spiroguanidines and their utility as α7 neuronal nicotinic acetylcholine receptor (nAChR) partial agonists. The convergent synthetic route developed for this study allowed for rapid SAR investigat
Autor:
Regina Miller, Michele Matchett, Nicholas J. Lodge, Yulia Benitex, Thaddeus F. Molski, Wendy Clarke, John E. Macor, Rulin Zhao, Robert Zaczek, Linda J. Bristow, Amy Easton, Christiana I. Iwuagwu, JoAnne E Natale, Haiquan Fang, Ronald J. Knox, Baoqing Ma, F. Christopher Zusi, Siva Digavalli, James H. Cook, Matthew D. Hill, Francine L. Healy, Debra J. Post-Munson, Jingfang Qian Cutrone, Daniel G. Morgan, Bei Wang, Richard E. Olson, Qi Gao, Rex Denton, Robert A. Mate, Ivar M. McDonald, Dalton King, Meredith Ferrante, Kimberley A. Lentz, Kelli M. Jones, Judith A. Siuciak, Lizbeth Gallagher
Publikováno v:
Journal of medicinal chemistry. 59(24)
The design and synthesis of a series of quinuclidine-containing spirooxazolidines (“spiroimidates”) and their utility as α7 nicotinic acetylcholine receptor partial agonists are described. Selected members of the series demonstrated excellent se
Autor:
Ping Chen, Digavalli V. Sivarao, Mikhail Frenkel, Robert Zaczek, Francine L. Healy, Nicholas J. Lodge
Publikováno v:
Neuropharmacology. 73:1-9
Patients with schizophrenia show marked deficits in processing sensory inputs including a reduction in the generation and synchronization of 40 Hz gamma oscillations in response to steady-state auditory stimulation. Such deficits are not readily demo
Autor:
Nicholas J. Lodge, Joanne J. Bronson, John E. Macor, Thaddeus F. Molski, Robert Zaczek, Yu-Wen Li, James E. Grace, Francine L. Healy, Debra J. Post-Munson, Snjezana Lelas, Digavalli V. Sivarao, Richard A. Hartz
Publikováno v:
Neuropharmacology. 67
BMS-763534 is a potent (CRF(1) IC(50) = 0.4 nM) and selective (>1000-fold selectivity vs. all other sites tested) CRF(1) receptor antagonist (pA2 = 9.47 vs. CRF(1)-mediated cAMP production in Y79 cells). BMS-763534 accelerated the dissociation of (12